All In Biotech

Investigational drug · Phase 3

AAV2-hRPE65v2

Also called: voretigene neparvovec-rzyl

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Leber Congenital Amaurosis, Inherited Retinal Dystrophy Due to RPE65 Mutations.

Phase 3

Last checked: Nov 20, 2026Latest source record: Apr 29, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

5

Any phase or sponsor naming "AAV2-hRPE65v2"

First trial start

2010

Nov 2010

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "AAV2-hRPE65v2", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Leber Congenital Amaurosis
  • Inherited Retinal Dystrophy Due to RPE65 Mutations

Approved drugs for the same conditions: Rare and genetic disease · Ophthalmology

Largest trials

Live from ClinicalTrials.gov: studies naming "AAV2-hRPE65v2" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 80 on PubMed

Also in development for Leber Congenital Amaurosis

  • sepofarsenQR-110Phase 32 trials

    Laboratoires Thea · Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis

  • ATSN-101Phase 21 trial

    Atsena Therapeutics Inc. · Leber Congenital Amaurosis, LCA, LCA1

  • OCU400Phase 21 trial

    Ocugen · Retinitis Pigmentosa, Leber Congenital Amaurosis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.